Sacituzumab govitecan (SG) has demonstrated real-world effectiveness in heavily pretreated patients with metastatic breast cancer (MBC), with outcomes consistent with prior registrational trials, according to research published in ESMO Open. The findings also suggest that plasma-based DNADX tumor subtypes may help predict response to treatment.
“SG is currently approved for patients with both triple-negative and hormone receptor (HR)-positive, [human epidermal growth factor receptor 2 (HER2)]-negative [MBC] following the positive results of the ASCENT and TROPICS-02 studies, which both showed a significant improvement in progression-free survival (PFS) and overall survival (OS) compared with single-agent chemotherapy,” explained the study authors. “However, observational data on efficacy of SG are limited, and biomarkers predictive of response and resistance to SG are lacking.”
The investigators conducted a retrospective, observational, single-center study of consecutive patients with MBC treated with SG monotherapy between June 2014 and January 2023 at a major academic US cancer center.
